Viral Hepatitis
Copyright ©The Author(s) 2003.
World J Gastroenterol. Sep 15, 2003; 9(9): 2012-2016
Published online Sep 15, 2003. doi: 10.3748/wjg.v9.i9.2012
Table 1 Clinical data for patients with HBV and/or HCV infection
Group BCGroup BGroup CStatistical value
Number of patients401631
Sex (male/female)21/196/1015/16χ2 = 1.030, P > 0.05
Age (y)a39 ± 5 (29-50)40 ± 6 (31-53)39 ± 3 (32-44)F = 0.48, P > 0.05
Time of infection (y)a16 ± 5 (14-21)16 ± 5 (14-21)17 ± 4 (14-21)F = 2.27, P > 0.05
Serological markers (1994)
HBsAg +34 (85.0%)16 (100%)0
HBeAg +11 (27.5%)7 (43.8%)0
HBVDNA +37 (92.5%)14 (87.5%)0
HCVRNA +11 (27.5%)0 (0%)19 (61.3%)
Anti-HCV39 (97.5%)0 (0%)31 (100.0%)
Table 2 Clearance of serum HBV markers in Group BC and Group B
Group BC (n = 40, %)Group B (n = 16, %)
HBsAg clearance
Until 19946 (15%)0 (0%)
Until 200227 (67.5%)8 (50%)
HBeAg clearance/seroconversion
HBeAg clearance
Until 199429 (72.5%)10 (62.5%)
Until 200237 (92.5%)14 (87.5%)
HBeAg seroconversion22 (55.5%)12 (75%)
HBV DNA clearance
Until 19943 (7.5%)2 (12.5%)
Until 200235 (87.5%)13 (81.2%)
HBV clearance27 (67.5%)7 (43.8%)
Male18 (85.7%)a4 (66.7%)
Female9 (47.4%)b3 (30%)
Low HBV DNA level group (< 105 copies/mL)17 (70.8%)4 (57.1%)
High HBV DNA level group (≥ 105 copies/mL)10 (62.5%)3 (33.3%)
Table 3 HCV RNA clearance rate in Group BC and Group C
Group BC (n = 40, %)Group C (n = 31, %)Statistics value
HCV RNA clearance
Until 199429 (72.5%)a12 (38.7%)bχ2 = 8.173, (a vs. b) P < 0.05
Until 200235 (87.5%)c10 (32.3%)dχ2 = 22.963, (c vs. d) P < 0.001
Male17 (80.9%)3 (20%)
Female18 (94.7%)7 (43.8%)
Table 4 Relationship of serum HBV and HCV load in 1994
HCV RNA (copies/mL)HBV DNA(copies/mL)
Total amount
< 103103-105≥ 105
< 1032141228
103-1051539
≥ 1050213
Total amount3211640
Table 5 Type B ultrasonic presentations in patients with HBV and/or HCV infection
NormalMildMediumSevereFatty liverNot detectedTotal
Group BC402133010
Group B80203313
Group C0131412131